| 1 |
34997449 | Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS). | 2022 May |
1 |
| 2 |
35050435 | Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study. | 2022 Jul |
1 |
| 3 |
35149429 | Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial. | 2022 Feb |
1 |
| 4 |
35182029 | The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study. | 2022 Jun |
1 |
| 5 |
35278170 | An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer. | 2022 Jun |
1 |
| 6 |
35474007 | Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS). | 2022 Jun |
1 |
| 7 |
33021466 | Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial. | 2021 Aug |
1 |
| 8 |
33464133 | Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer. | 2021 May |
1 |
| 9 |
33544407 | A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer. | 2021 Feb |
1 |
| 10 |
33569986 | Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. | 2021 Jun |
1 |
| 11 |
33713215 | Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study. | 2021 Jul |
1 |
| 12 |
33780084 | Monitoring FTD in the peripheral blood mononuclear cells of elderly patients with metastatic colorectal cancer administered FTD plus bevacizumab as first-line treatment. | 2021 Jun |
1 |
| 13 |
33952483 | Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience. | 2021 May |
1 |
| 14 |
33993741 | A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer. | 2021 Sep |
1 |
| 15 |
34097100 | A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment. | 2021 Sep |
1 |
| 16 |
34175675 | Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. | 2021 Aug |
1 |
| 17 |
34406678 | Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center. | 2021 Dec |
1 |
| 18 |
34547581 | Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study. | 2021 Oct |
2 |
| 19 |
34848475 | The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting. | 2021 Dec |
1 |
| 20 |
30838483 | A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study. | 2020 Feb |
1 |
| 21 |
31591140 | Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib. | 2020 Jan |
2 |
| 22 |
31600365 | Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial. | 2020 Jan 1 |
1 |
| 23 |
31826977 | Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. | 2020 May |
4 |
| 24 |
31838590 | Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. | 2020 Apr |
1 |
| 25 |
32371587 | Synthetic Lethality with Trifluridine/Tipiracil and Checkpoint Kinase 1 Inhibitor for Esophageal Squamous Cell Carcinoma. | 2020 Jun |
1 |
| 26 |
32530932 | Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan. | 2020 |
1 |
| 27 |
32816155 | Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study. | 2020 Sep |
1 |
| 28 |
32891715 | Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine/tipiracil and X-rays. | 2020 Nov 28 |
1 |
| 29 |
33173384 | Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil. | 2020 Oct |
1 |
| 30 |
30628113 | Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment. | 2019 Jun |
1 |
| 31 |
31611243 | Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. | 2019 Dec |
1 |
| 32 |
32392174 | Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer. | 2019 Nov |
1 |
| 33 |
29515409 | Beneficial Treatment Management with Trifluridine/Tipiracil in a Patient with Metastatic Colorectal Cancer and Pronounced Hematological Event History during Previous Treatments. | 2018 Jan-Apr |
1 |
| 34 |
29568368 | Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression. | 2018 Mar 2 |
2 |
| 35 |
30257515 | Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells. | 2018 Sep 25 |
1 |
| 36 |
30350179 | Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. | 2018 Dec |
1 |
| 37 |
30445951 | Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer. | 2018 Nov 16 |
1 |
| 38 |
29312810 | Combined efficacy and mechanism of trifluridine and SN-38 in a 5-FU-resistant human colorectal cancer cell lines. | 2017 |
2 |